Review





Similar Products

96
Santa Cruz Biotechnology antibodies against vascular cell adhesion molecule 1
Antibodies Against Vascular Cell Adhesion Molecule 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM-1+Antibody/10__1007_slash_s11694___026___04897___4-90-7-14
Average 96 stars, based on 1 article reviews
antibodies against vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
ABclonal Biotechnology vascular cell adhesion molecule 1
Vascular Cell Adhesion Molecule 1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM1+Rabbit+pAb/pmc13545767-130-103-109
Average 94 stars, based on 1 article reviews
vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Cusabio vcam1
Study design and workflow for biomarker discovery and validation. An overview of the integrative pipeline combining proteome-wide pQTL data from 8 large-scale proteomic studies with 3 cardiomyopathy GWAS datasets (UKB–PCM, FinnGen–NICM, and FinnGen–RCM) using Mendelian randomization (MR). After harmonization, filtering, and instrument selection, 13,636 pQTLs (2,157 cis and 11,479 trans) across 5,034 proteins were evaluated. A multi-dimensional scoring system based on replication consistency, effect size, P -value, and literature evidence was used to prioritize candidate proteins for clinical validation. Five proteins (CD163, LGALS3BP, FABP5, FSTL3, and <t>VCAM1)</t> were selected for ELISA testing (48 CM patients, 33 healthy controls); subsequent panel refinement yielded a parsimonious 4-protein panel as the primary combined model. The pleiotropy-screening traits were used for instrument screening to mitigate horizontal pleiotropy, rather than representing a comprehensive list of clinical differential diagnoses.
Vcam1, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/Human+Vascular+cell+adhesion+molecule+1%2CVCAM-1+ELISA+kit/pmc13746034-120-27-28
Average 93 stars, based on 1 article reviews
vcam1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc vascular cell adhesion molecule 1 vcam 1
Study design and workflow for biomarker discovery and validation. An overview of the integrative pipeline combining proteome-wide pQTL data from 8 large-scale proteomic studies with 3 cardiomyopathy GWAS datasets (UKB–PCM, FinnGen–NICM, and FinnGen–RCM) using Mendelian randomization (MR). After harmonization, filtering, and instrument selection, 13,636 pQTLs (2,157 cis and 11,479 trans) across 5,034 proteins were evaluated. A multi-dimensional scoring system based on replication consistency, effect size, P -value, and literature evidence was used to prioritize candidate proteins for clinical validation. Five proteins (CD163, LGALS3BP, FABP5, FSTL3, and <t>VCAM1)</t> were selected for ELISA testing (48 CM patients, 33 healthy controls); subsequent panel refinement yielded a parsimonious 4-protein panel as the primary combined model. The pleiotropy-screening traits were used for instrument screening to mitigate horizontal pleiotropy, rather than representing a comprehensive list of clinical differential diagnoses.
Vascular Cell Adhesion Molecule 1 Vcam 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM-1+Rabbit+mAb/pm41832379-106-13-19
Average 94 stars, based on 1 article reviews
vascular cell adhesion molecule 1 vcam 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc vascular cell adhesion molecule 1
Study design and workflow for biomarker discovery and validation. An overview of the integrative pipeline combining proteome-wide pQTL data from 8 large-scale proteomic studies with 3 cardiomyopathy GWAS datasets (UKB–PCM, FinnGen–NICM, and FinnGen–RCM) using Mendelian randomization (MR). After harmonization, filtering, and instrument selection, 13,636 pQTLs (2,157 cis and 11,479 trans) across 5,034 proteins were evaluated. A multi-dimensional scoring system based on replication consistency, effect size, P -value, and literature evidence was used to prioritize candidate proteins for clinical validation. Five proteins (CD163, LGALS3BP, FABP5, FSTL3, and <t>VCAM1)</t> were selected for ELISA testing (48 CM patients, 33 healthy controls); subsequent panel refinement yielded a parsimonious 4-protein panel as the primary combined model. The pleiotropy-screening traits were used for instrument screening to mitigate horizontal pleiotropy, rather than representing a comprehensive list of clinical differential diagnoses.
Vascular Cell Adhesion Molecule 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM-1+Rabbit+mAb/pmc12957846-46-18-39
Average 94 stars, based on 1 article reviews
vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mouse monoclonal anti vascular cell adhesion molecule 1
Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular <t>adhesion</t> <t>molecule-1</t> (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).
Mouse Monoclonal Anti Vascular Cell Adhesion Molecule 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM-1+Antibody/pmc12956526-92-140-150
Average 96 stars, based on 1 article reviews
mouse monoclonal anti vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc vascular cell adhesion molecule 1 vcam 1 antibody
Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular <t>adhesion</t> <t>molecule-1</t> (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).
Vascular Cell Adhesion Molecule 1 Vcam 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/VCAM-1+Antibody/pm41689678-103-12-35
Average 95 stars, based on 1 article reviews
vascular cell adhesion molecule 1 vcam 1 antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Biorbyt vascular cell adhesion molecule 1
Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular <t>adhesion</t> <t>molecule-1</t> (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).
Vascular Cell Adhesion Molecule 1, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/IRS1+(phospho-Ser332%2F336)+antibody/pmc12768481-75-31-40
Average 93 stars, based on 1 article reviews
vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems vascular cell adhesion molecule 1
Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular <t>adhesion</t> <t>molecule-1</t> (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).
Vascular Cell Adhesion Molecule 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/Human+VCAM-1%2FCD106+DuoSet+ELISA/pmc12897947-358-21-56
Average 94 stars, based on 1 article reviews
vascular cell adhesion molecule 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Study design and workflow for biomarker discovery and validation. An overview of the integrative pipeline combining proteome-wide pQTL data from 8 large-scale proteomic studies with 3 cardiomyopathy GWAS datasets (UKB–PCM, FinnGen–NICM, and FinnGen–RCM) using Mendelian randomization (MR). After harmonization, filtering, and instrument selection, 13,636 pQTLs (2,157 cis and 11,479 trans) across 5,034 proteins were evaluated. A multi-dimensional scoring system based on replication consistency, effect size, P -value, and literature evidence was used to prioritize candidate proteins for clinical validation. Five proteins (CD163, LGALS3BP, FABP5, FSTL3, and VCAM1) were selected for ELISA testing (48 CM patients, 33 healthy controls); subsequent panel refinement yielded a parsimonious 4-protein panel as the primary combined model. The pleiotropy-screening traits were used for instrument screening to mitigate horizontal pleiotropy, rather than representing a comprehensive list of clinical differential diagnoses.

Journal: Anatolian Journal of Cardiology

Article Title: Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical Validation

doi: 10.14744/AnatolJCardiol.2026.5927

Figure Lengend Snippet: Study design and workflow for biomarker discovery and validation. An overview of the integrative pipeline combining proteome-wide pQTL data from 8 large-scale proteomic studies with 3 cardiomyopathy GWAS datasets (UKB–PCM, FinnGen–NICM, and FinnGen–RCM) using Mendelian randomization (MR). After harmonization, filtering, and instrument selection, 13,636 pQTLs (2,157 cis and 11,479 trans) across 5,034 proteins were evaluated. A multi-dimensional scoring system based on replication consistency, effect size, P -value, and literature evidence was used to prioritize candidate proteins for clinical validation. Five proteins (CD163, LGALS3BP, FABP5, FSTL3, and VCAM1) were selected for ELISA testing (48 CM patients, 33 healthy controls); subsequent panel refinement yielded a parsimonious 4-protein panel as the primary combined model. The pleiotropy-screening traits were used for instrument screening to mitigate horizontal pleiotropy, rather than representing a comprehensive list of clinical differential diagnoses.

Article Snippet: All plasma samples were analyzed using commercially available sandwich ELISA kits for 8 proteins: CD163 (Proteintech, KE00190), LGALS3BP (Proteintech, KE00155), FABP5 (CUSABIO, CSB-EL007946HU), FSTL3 (Thermo Fisher, EHFSTL3), VCAM1 (CUSABIO, CSB-E04753h), PICP (Cloud-Clone, SEA573Hu), Galectin-3 (Proteintech, KE00126), and PIIINP (Cloud-Clone, SEA570Hu).

Techniques: Biomarker Discovery, Selection, Enzyme-linked Immunosorbent Assay, Screening, Significance Assay

Forest plots of odds ratios for candidate proteins across 3 cardiomyopathy GWAS datasets. Forest plots showing mendelian randomization-derived odds ratios (ORs) and 95% confidence intervals (CIs) for each candidate protein (CD163, LGALS3BP, FABP5, FSTL3, VCAM1) across UKB–Primary Cardiomyopathy (PCM), FinnGen Non-ischemic Cardiomyopathy (NICM), FinnGen Restrictive Cardiomyopathy (RCM), and the combined meta-analysis. Directionally consistent associations and pooled effects support the potential causal relevance of these proteins to cardiomyopathy risk.

Journal: Anatolian Journal of Cardiology

Article Title: Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical Validation

doi: 10.14744/AnatolJCardiol.2026.5927

Figure Lengend Snippet: Forest plots of odds ratios for candidate proteins across 3 cardiomyopathy GWAS datasets. Forest plots showing mendelian randomization-derived odds ratios (ORs) and 95% confidence intervals (CIs) for each candidate protein (CD163, LGALS3BP, FABP5, FSTL3, VCAM1) across UKB–Primary Cardiomyopathy (PCM), FinnGen Non-ischemic Cardiomyopathy (NICM), FinnGen Restrictive Cardiomyopathy (RCM), and the combined meta-analysis. Directionally consistent associations and pooled effects support the potential causal relevance of these proteins to cardiomyopathy risk.

Article Snippet: All plasma samples were analyzed using commercially available sandwich ELISA kits for 8 proteins: CD163 (Proteintech, KE00190), LGALS3BP (Proteintech, KE00155), FABP5 (CUSABIO, CSB-EL007946HU), FSTL3 (Thermo Fisher, EHFSTL3), VCAM1 (CUSABIO, CSB-E04753h), PICP (Cloud-Clone, SEA573Hu), Galectin-3 (Proteintech, KE00126), and PIIINP (Cloud-Clone, SEA570Hu).

Techniques: Derivative Assay, Analysis

Baseline Characteristics, Plasma Biomarkers, and Echocardiographic Parameters of Study Participants

Journal: Anatolian Journal of Cardiology

Article Title: Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical Validation

doi: 10.14744/AnatolJCardiol.2026.5927

Figure Lengend Snippet: Baseline Characteristics, Plasma Biomarkers, and Echocardiographic Parameters of Study Participants

Article Snippet: All plasma samples were analyzed using commercially available sandwich ELISA kits for 8 proteins: CD163 (Proteintech, KE00190), LGALS3BP (Proteintech, KE00155), FABP5 (CUSABIO, CSB-EL007946HU), FSTL3 (Thermo Fisher, EHFSTL3), VCAM1 (CUSABIO, CSB-E04753h), PICP (Cloud-Clone, SEA573Hu), Galectin-3 (Proteintech, KE00126), and PIIINP (Cloud-Clone, SEA570Hu).

Techniques: Clinical Proteomics

Association of Plasma Protein Levels with Cardiomyopathy Risk: Univariate and Multivariate Logistic Regression <.001

Journal: Anatolian Journal of Cardiology

Article Title: Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical Validation

doi: 10.14744/AnatolJCardiol.2026.5927

Figure Lengend Snippet: Association of Plasma Protein Levels with Cardiomyopathy Risk: Univariate and Multivariate Logistic Regression <.001

Article Snippet: All plasma samples were analyzed using commercially available sandwich ELISA kits for 8 proteins: CD163 (Proteintech, KE00190), LGALS3BP (Proteintech, KE00155), FABP5 (CUSABIO, CSB-EL007946HU), FSTL3 (Thermo Fisher, EHFSTL3), VCAM1 (CUSABIO, CSB-E04753h), PICP (Cloud-Clone, SEA573Hu), Galectin-3 (Proteintech, KE00126), and PIIINP (Cloud-Clone, SEA570Hu).

Techniques: Clinical Proteomics

Clinical validation of candidate biomarkers in a prospective cohort. (A) Spearman correlation heatmap showing associations between plasma biomarker levels (CD163, LGALS3BP, FABP5, FSTL3, VCAM1) and echocardiographic parameters (LVEDD, LA, IVS, LVEF, FS, E/A ratio). Red indicates positive correlations; blue indicates negative correlations. (B) Receiver operating characteristic (ROC) curves for the 4 individual proteins (CD163, LGALS3BP, FABP5, and FSTL3) and the combined 4-protein panel. The combined model achieved an apparent (in-sample) AUC of 0.993; given the modest sample size and case–control design, apparent performance may be optimistic. Optimism-corrected and repeated cross-validated AUCs are reported in Supplementary Table 2, and external validation is warranted.

Journal: Anatolian Journal of Cardiology

Article Title: Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical Validation

doi: 10.14744/AnatolJCardiol.2026.5927

Figure Lengend Snippet: Clinical validation of candidate biomarkers in a prospective cohort. (A) Spearman correlation heatmap showing associations between plasma biomarker levels (CD163, LGALS3BP, FABP5, FSTL3, VCAM1) and echocardiographic parameters (LVEDD, LA, IVS, LVEF, FS, E/A ratio). Red indicates positive correlations; blue indicates negative correlations. (B) Receiver operating characteristic (ROC) curves for the 4 individual proteins (CD163, LGALS3BP, FABP5, and FSTL3) and the combined 4-protein panel. The combined model achieved an apparent (in-sample) AUC of 0.993; given the modest sample size and case–control design, apparent performance may be optimistic. Optimism-corrected and repeated cross-validated AUCs are reported in Supplementary Table 2, and external validation is warranted.

Article Snippet: All plasma samples were analyzed using commercially available sandwich ELISA kits for 8 proteins: CD163 (Proteintech, KE00190), LGALS3BP (Proteintech, KE00155), FABP5 (CUSABIO, CSB-EL007946HU), FSTL3 (Thermo Fisher, EHFSTL3), VCAM1 (CUSABIO, CSB-E04753h), PICP (Cloud-Clone, SEA573Hu), Galectin-3 (Proteintech, KE00126), and PIIINP (Cloud-Clone, SEA570Hu).

Techniques: Biomarker Discovery, Clinical Proteomics, Control

Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular adhesion molecule-1 (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).

Journal: Frontiers in Immunology

Article Title: Dysregulated hyaluronan metabolism drives inflammation and angiogenesis in proliferative diabetic retinopathy

doi: 10.3389/fimmu.2026.1724199

Figure Lengend Snippet: Expression levels of hyaluronidase (Hyal)-1 (A) , CD44 (B) and receptor for hyaluronan-mediated motility (RHAMM) (C) in the retinal lysates of non-diabetic control rats (C) (n=12) and diabetic rats (D) (n=12) were determined by Western blot analysis. After determination of the intensity of the protein bands, intensities were adjusted to those of β-actin in the samples. Oxidative stress was monitored with the use of 2’,7’-Dichlorofluorescein (DCF) fluorescence intensity analysis (D) . Results are expressed as mean ± standard deviation. Ultra-Low molecular weight hyaluronan (ULMW-HA) induces breakdown of blood-retinal barrier (E) . ULMW-HA was injected intravitreally at the dose of 50 ng in 5 µL in one eye and the same volume of phosphate-buffered saline (PBS) was injected in the contralateral eye of normal rats. The BRB was quantified with the fluorescein isothiocyanate-conjugated dextran technique. Results are expressed as mean ± standard deviation of 12 rats. *p < 0.05 compared to the values obtained from PBS-injected eyes. (independent t-test). Western blot analysis of retinas demonstrated that intravitreal injection of ULMW-HA induced significant upregulation of the expression of phospho-NF-κB (F) , phospho-ERK1/2 (G) , vascular endothelial growth factor (VEGF) (H) , intercellular adhesion molecule-1 (ICAM-1) (I) , vascular cell adhesion molecule-1 (VCAM-1) (J) and high-mobility group box-1 (HMGB1) (K) . Results are expressed as mean ± standard deviation or standard error of mean of 8–10 rats in each group (*p < 0.05; independent t-test).

Article Snippet: To determine the presence of Hyal-1, Hyal-2, HAS2, CD44, syndecan-1, heparan sulphate and RHAMM in the vitreous samples, equal volumes (10 μL) of vitreous samples were boiled in Laemmli’s sample buffer (1:1, v/v) under reducing condition for 10 min. Immunodetection was performed with the use of rabbit polyclonal anti-Hyal-1 antibody (1:1000, NBP2-16906, Novus Biologicals), mouse polyclonal anti-Hyal-2 antibody (1:1000, H00008692-B02P, Novus Biologicals), mouse monoclonal anti-HAS2 antibody (1:1000, ab140671, Abcam), rabbit monoclonal anti-CD44 antibody (1:1000, ab189524, Abcam), rabbit monoclonal anti-RHAMM antibody (1:1000, ab124729, Abcam), rabbit monoclonal anti-phospho-extracellular signal-regulated kinase (ERK)1/2 antibody (1:1000, MAB1018, R&D Systems), rabbit polyclonal anti-p65 subunit of nuclear factor-kappa B (phospho-NF-κB) (1:1000, NB100-82086, Novus Biologicals), rabbit polyclonal anti-high-mobility group box1 (HMGB1) (1:1000, Cat. no. ab18256, Abcam), mouse monoclonal anti-VEGF antibody (1:750, MAB293, R&D Systems), mouse monoclonal anti-intercellular adhesion molecule-1 (ICAM-1) antibody (1:100, sc-8439, Santa Cruz Biotechnology Inc.), and mouse monoclonal anti-vascular cell adhesion molecule-1 (VCAM-1) antibody (1:100, sc-13160, Santa Cruz Biotechnology Inc.).

Techniques: Expressing, Control, Western Blot, Fluorescence, Standard Deviation, Molecular Weight, Injection, Saline

Human retinal microvascular endothelial cells (HRMECs) were left untreated or stimulated with tumor necrosis factor-α (TNF-α) (5 ng/mL) for 24 h with or without apigenin (10 µg/mL). Protein expression of intercellular adhesion molecule-1 (ICAM-1) (A) and vascular cell adhesion molecule-1 (VCAM-1) (B) was determined by Western blot analysis. Adhesion of fluorescently labeled THP-1 monocytic cells to HRMECs monolayer was quantified (C) . Results are expressed as mean ± standard deviation or standard error of mean from three different experiments each performed in triplicate. One-way ANOVA and independent t-test were used for comparisons between three groups and two groups, respectively. *p < 0.05 compared with values obtained from untreated cells. #p < 0.05 compared with values obtained from cells treated with TNF-α (RFU = relative fluorescence unit).

Journal: Frontiers in Immunology

Article Title: Dysregulated hyaluronan metabolism drives inflammation and angiogenesis in proliferative diabetic retinopathy

doi: 10.3389/fimmu.2026.1724199

Figure Lengend Snippet: Human retinal microvascular endothelial cells (HRMECs) were left untreated or stimulated with tumor necrosis factor-α (TNF-α) (5 ng/mL) for 24 h with or without apigenin (10 µg/mL). Protein expression of intercellular adhesion molecule-1 (ICAM-1) (A) and vascular cell adhesion molecule-1 (VCAM-1) (B) was determined by Western blot analysis. Adhesion of fluorescently labeled THP-1 monocytic cells to HRMECs monolayer was quantified (C) . Results are expressed as mean ± standard deviation or standard error of mean from three different experiments each performed in triplicate. One-way ANOVA and independent t-test were used for comparisons between three groups and two groups, respectively. *p < 0.05 compared with values obtained from untreated cells. #p < 0.05 compared with values obtained from cells treated with TNF-α (RFU = relative fluorescence unit).

Article Snippet: To determine the presence of Hyal-1, Hyal-2, HAS2, CD44, syndecan-1, heparan sulphate and RHAMM in the vitreous samples, equal volumes (10 μL) of vitreous samples were boiled in Laemmli’s sample buffer (1:1, v/v) under reducing condition for 10 min. Immunodetection was performed with the use of rabbit polyclonal anti-Hyal-1 antibody (1:1000, NBP2-16906, Novus Biologicals), mouse polyclonal anti-Hyal-2 antibody (1:1000, H00008692-B02P, Novus Biologicals), mouse monoclonal anti-HAS2 antibody (1:1000, ab140671, Abcam), rabbit monoclonal anti-CD44 antibody (1:1000, ab189524, Abcam), rabbit monoclonal anti-RHAMM antibody (1:1000, ab124729, Abcam), rabbit monoclonal anti-phospho-extracellular signal-regulated kinase (ERK)1/2 antibody (1:1000, MAB1018, R&D Systems), rabbit polyclonal anti-p65 subunit of nuclear factor-kappa B (phospho-NF-κB) (1:1000, NB100-82086, Novus Biologicals), rabbit polyclonal anti-high-mobility group box1 (HMGB1) (1:1000, Cat. no. ab18256, Abcam), mouse monoclonal anti-VEGF antibody (1:750, MAB293, R&D Systems), mouse monoclonal anti-intercellular adhesion molecule-1 (ICAM-1) antibody (1:100, sc-8439, Santa Cruz Biotechnology Inc.), and mouse monoclonal anti-vascular cell adhesion molecule-1 (VCAM-1) antibody (1:100, sc-13160, Santa Cruz Biotechnology Inc.).

Techniques: Expressing, Western Blot, Labeling, Standard Deviation, Fluorescence